Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 633
Filter
1.
J Med Case Rep ; 18(1): 141, 2024 Mar 08.
Article in English | MEDLINE | ID: mdl-38454461

ABSTRACT

INTRODUCTION: Intermuscular hydatid cyst is one of the rarest types of hydatid cyst, and as far as we know, only nine cases were reported in the literature before this study. CASE PRESENTATION: We present a 10-year-old Iranian child with an intermuscular cystic mass in the medial-distal thigh. Despite the typical imaging findings, the patient's serological and hematological tests were negative for hydatid cyst. The cyst underwent wide excision accompanied by neoadjuvant and adjuvant chemotherapy with Albendazole. No evidence of recurrence was detected during the one-year follow-up. CONCLUSION: Hydatid cysts should always be considered in the differential diagnosis of soft tissue cystic masses in endemic areas, and aspiration or drainage should be avoided as much as possible, even when serological tests are negative and imaging is non-diagnostic. In cases where the diagnosis of a hydatid cyst has been confirmed before the surgery, it is recommended to approach the cyst, like a tumor with chemotherapy using Albendazole both before and after wide cyst excision.


Subject(s)
Cysts , Echinococcosis , Child , Humans , Albendazole/therapeutic use , Iran , Echinococcosis/diagnosis , Echinococcosis/therapy , Echinococcosis/pathology , Diagnostic Imaging
2.
Curr Opin Infect Dis ; 36(5): 308-317, 2023 10 01.
Article in English | MEDLINE | ID: mdl-37548385

ABSTRACT

PURPOSE OF REVIEW: The aim is to review recent literature for percutaneous treatment of liver hydatid cysts (cystic echinococcosis: CE) via different techniques such as PAIR (puncture, aspiration, injection, and reaspiration), standard catheterization, and modified catheterization technique (MoCaT). RECENT FINDINGS: PAIR is an established technique and considered to be safe and effective for CE1 and CE3a as it is associated with lower morbidity, mortality, recurrence, and shorter hospital stay as compared with surgery. Standard catheterization is also dedicated for the treatment of CE1 and CE3a. PAIR should be preferred for treatment of liver CE1 and CE3a cysts, since PAIR is associated with lower major complication rates and shorter hospital stay. However, standard catheterization technique is indicated when cysto-biliary fistula develops or any technical difficulty arises during the PAIR. In these cases it is needed to switch PAIR to standard catheterization to complete the procedure. SUMMARY: For CE1 and CE3a cysts, PAIR and standard catheterization are the choice for percutaneous treatments, while MoCaT is a treatment option for CE2 and CE3b cysts.


Subject(s)
Cysts , Echinococcosis, Hepatic , Echinococcosis , Humans , Suction/methods , Treatment Outcome , Echinococcosis, Hepatic/surgery , Echinococcosis/therapy
3.
Curr Opin Infect Dis ; 36(5): 341-347, 2023 10 01.
Article in English | MEDLINE | ID: mdl-37593962

ABSTRACT

PURPOSE OF REVIEW: Cystic echinococcosis (CE) has a wide world distribution causing important morbidity. Osseous involvement is present in less than 4% of the CE cases. Its diagnosis and therapeutic management is full of challenges and low grade of evidence. RECENT FINDINGS: The study summarizes literature evidence on the management of osseous CE with particular emphasis on new data regarding diagnosis and treatment. SUMMARY: Clinical presentation of osseous CE depends on the skeletal area affected. Diagnosis is mostly based on radiological findings and serology. Recent advances with qPCR on osseous tissue samples seem to be a good option for diagnosis confirmation. Complete resection of the cystic lesion is the only curative option, but it is usually not possible performing palliative surgery and prolonged albendazole intake in most cases. Radiotherapy could be an option, but experience to date is only based on clinical cases.


Subject(s)
Echinococcosis , Humans , Echinococcosis/diagnostic imaging , Echinococcosis/therapy , Albendazole/therapeutic use
4.
Rev Med Suisse ; 19(822): 708-712, 2023 Apr 12.
Article in French | MEDLINE | ID: mdl-37057851

ABSTRACT

Alveolar echinococcosis is a rare but severe parasitic disease and is now in Europe the parasitic infection associated with the most morbidity and mortality. Its prevalence is increasing in Switzerland in both urban and rural areas. Echinococcosis is a differential diagnosis that should be considered when facing a cystic hepatic lesion. Moreover, this parasitic infection is increasing amongst immunocompromised patients, making the diagnosis more complex, because of atypic lesions and a more rapid evolution. At the current time, several treatment options, both surgical and medical, can offer patients a good prognosis and maintain a good quality of life.


L'échinococcose alvéolaire est une parasitose rare mais sévère. En Europe, il s'agit de l'infection parasitaire causant le plus de morbimortalité. Son incidence est en augmentation en Suisse dans les zones urbaines et rurales. L'échinococcose est donc un diagnostic différentiel à évoquer face à une lésion kystique hépatique. En outre, cette infection parasitaire est en augmentation chez les patients immunosupprimés, chez qui le diagnostic est plus complexe en raison de lésions atypiques et d'une évolution plus rapide. À l'heure actuelle, plusieurs modalités de traitements chirurgicaux et médicamenteux permettent d'offrir un bon pronostic aux patients tout en maintenant une bonne qualité de vie.


Subject(s)
Echinococcosis, Hepatic , Echinococcosis , Humans , Echinococcosis, Hepatic/diagnosis , Echinococcosis, Hepatic/epidemiology , Echinococcosis, Hepatic/therapy , Quality of Life , Echinococcosis/diagnosis , Echinococcosis/epidemiology , Echinococcosis/therapy
5.
Exp Parasitol ; 249: 108501, 2023 Jun.
Article in English | MEDLINE | ID: mdl-36931383

ABSTRACT

BACKGROUND: Hydatid cyst is the larval stage of the tape worm Echinococcus granulosus which is located in human and livestock viscera. There are some scientific evidences indicating that parasitic infections induce antitumor activity against certain types of cancers. In this study, the effects of a fraction of hydatid cyst fluid on colon cancer tumor in BALB/c mice were investigated. MATERIALS AND METHODS: In this experimental work six groups of mice were challenged with mouse colon cancer cells. 5 days later when the sign of tumor growth in mice was seen, group 1-4 were injected with hydatid cyst fluid, the 78 kDa fraction, live protoscolices and BCG respectively. Group five was injected with alum alone and the sixth group left intact without any injection. The size of the tumor was measured and compared in all groups. Then blood samples of mice were evaluated for serum cytokine levels. RESULT: In mice injected with hydatid cyst antigens especially a fraction of hydatid cyst fluid, tumor size was smaller than the that of control groups and the difference of tumor size in cases and control groups was statistically significant. CONCLUSION: The results of this study showed that injection of mice with a fraction of hydatid cyst fluid significantly inhibits the growth of mouse colon cancer and this inhibition may be related to effect of immune response to these antigens.


Subject(s)
Colonic Neoplasms , Echinococcosis , Echinococcus granulosus , Echinococcus , Animals , Humans , Mice , Echinococcosis/therapy , Colonic Neoplasms/therapy , Immunotherapy
6.
Rev Med Liege ; 78(3): 153-159, 2023 Mar.
Article in French | MEDLINE | ID: mdl-36924153

ABSTRACT

Alveolar echinococcosis is an indigenouszoonosis caused by the growth of the larval stage of a small tapeworm, Echinococcus multilocularis. Despite a low incidence in Belgium, with about 10 cases on average recorded per year, this parasitosis poses a real public health problem because it often remains difficult to diagnose and is potentially fatal in the absence of treatment. General practitioners are on the frontline, but they do not always know enough about the disease, which causes a delay in the diagnosis and impacts the prognosis. The present study aims to assess the level of knowledge of alveolar echinococcosis among general practitioners in the province of Liège via a questionnaire, on the one hand, and to increase their level of knowledge via a formative intervention using a video capsule, on the other hand. We have performed a randomized controlled experimental study, which showed that general practitioners in the province of Liège have limited knowledge on alveolar echinococcosis. This mainly concerns symptomatology, diagnostic tools and treatment. The formative intervention carried out allowed increasing their level of knowledge about this disease.


L'échinococcose alvéolaire est une zoonose autochtone provoquée par le développement tissulaire de la larve d'un petit ténia, Echinoccocus multilocularis. Malgré une faible incidence en Belgique, avec une moyenne de 10 cas recensés par an, cette parasitose pose un réel problème de santé publique car elle reste souvent difficile à diagnostiquer et potentiellement mortelle en l'absence de traitement. Les médecins généralistes sont en première ligne, mais ils ne connaissent pas toujours suffisamment la maladie, ce qui retarde le diagnostic et compromet le pronostic. La présente étude visait à évaluer les connaissances à propos de l'échinococcose alvéolaire des médecins généralistes de la province de Liège via un questionnaire approprié et à accroître leur niveau de connaissance via une intervention formative sous forme de capsule vidéo. Nous avons réalisé une étude à visée expérimentale randomisée contrôlée qui a montré que les médecins généralistes de la province de Liège ont des connaissances partielles sur la symptomatologie, les outils de diagnostic et le traitement. L'intervention formative réalisée a permis d'augmenter leur niveau de connaissances à propos de cette maladie.


Subject(s)
Echinococcosis , Echinococcus multilocularis , General Practitioners , Animals , Humans , Echinococcosis/diagnosis , Echinococcosis/epidemiology , Echinococcosis/therapy , Belgium/epidemiology
7.
J Am Vet Med Assoc ; 261(7): 1-6, 2023 07 01.
Article in English | MEDLINE | ID: mdl-36800299

ABSTRACT

OBJECTIVE: To describe the clinical disease, diagnostic findings, medical management, and outcome in dogs with alveolar echinococcosis (AE). ANIMALS: 4 dogs with naturally occurring AE. PROCEDURES: Medical records were retrospectively reviewed from 2020 to 2022 to identify dogs diagnosed with AE. Signalment, case history, clinical signs, imaging and pathological laboratory findings, treatment, and clinical outcome were reported. RESULTS: All dogs developed systemic clinical illness and weight loss. Abdominal ultrasonography revealed multifocal to coalescent cystic masses of variable size distributed throughout the liver in all cases. Evaluation of aspirated hepatic cyst contents included membranous parasite structures and calcareous corpuscles. Echinococcus multilocularis was confirmed via PCR from hepatic cyst fluid in 3 of 4 cases. Treatment included systemic benzimidazole and praziquantel administration, 1 or more instances of ultrasound-guided cyst drainage in all cases, with ethanol ablation (percutaneous aspiration-injection-reaspiration) in 2 cases, and surgical resection in 1 case. Two of 4 dogs were euthanized within 5 months of diagnosis. One of these dogs was necropsied and had nearly complete obliteration of the hepatic parenchyma by multilocular cystic masses. One dog is still alive, and 1 dog has been lost to follow-up. CLINICAL RELEVANCE: This series of cases highlighted the diagnostic findings and therapeutic intervention in 4 dogs with AE. This was the first report of medical management incorporating the percutaneous aspiration-injection-reaspiration method used in humans. Reports of canine AE are rare in the US, so this series serves to help raise awareness of hepatic AE in the northwestern US.


Subject(s)
Cysts , Dog Diseases , Echinococcosis, Hepatic , Echinococcosis , Humans , Dogs , Animals , Retrospective Studies , Echinococcosis/diagnosis , Echinococcosis/therapy , Echinococcosis/veterinary , Echinococcosis, Hepatic/diagnosis , Echinococcosis, Hepatic/therapy , Echinococcosis, Hepatic/veterinary , Cysts/veterinary , Dog Diseases/therapy , Dog Diseases/drug therapy
8.
Childs Nerv Syst ; 39(3): 751-758, 2023 03.
Article in English | MEDLINE | ID: mdl-36443475

ABSTRACT

Hydatid disease of the central nervous system is relatively rare and comprises about 2-3% of all the hydatid cyst cases reported in the world. Spinal hydatid disease is an even rarer entity. It is endemic in sheep and cattle-raising regions, seen mainly in Mediterranean countries including Turkey and Syria. Pediatric neurosurgeons in non-endemic countries face a challenge when they encounter children with hydatid cysts of the central nervous system, mostly due to lack of awareness and the ensuing diagnostic dilemmas. It is also a significant socioeconomic problem in developing countries, due to improper hygiene and lack of dedicated veterinary practice. The clinical features are largely nonspecific and very according to location and severity of disease. However, with the advent of advances in MR imaging, the diagnostic accuracy of hydatic disease involving the brain and spine has increased. Intact removal of the cyst/s, without causing any spillage, and appropriate antihelminthic therapy is the goal and key to cure and prevention of recurrence. In this manuscript, the current literature on hydatid cyst of the brain and spine is reviewed to better understand the epidemiology, pathophysiology, diagnostic accuracy, and advances in therapeutic options. A heightened clinical suspicion, awareness of MR imaging features, improved surgical strategies, and options for prevention are discussed.


Subject(s)
Echinococcosis , Spinal Diseases , Animals , Sheep , Cattle , Echinococcosis/diagnostic imaging , Echinococcosis/epidemiology , Echinococcosis/therapy , Brain/diagnostic imaging , Spine , Magnetic Resonance Imaging , Spinal Diseases/diagnostic imaging , Spinal Diseases/epidemiology , Spinal Diseases/therapy
9.
Indian J Gastroenterol ; 41(6): 643-648, 2022 12.
Article in English | MEDLINE | ID: mdl-36484785

ABSTRACT

Hydatid cyst (HC) is uncommon in children and usually involves a single organ, the lung being the most common site followed by the liver. A series of 18 children who presented with HC at different organs of the body managed at our institute over a period of 5 years is presented here. The clinico-radiological evaluation was done in all patients followed by pharmacotherapy/surgery and was followed up for 2 years. Demographic data, organs of involvement, clinical presentations and investigations, response to oral albendazole therapy, surgical procedures, operative findings, perioperative clinical courses, and surgical outcomes were recorded. The mean age of presentation was 7.7 years with a male:female ratio of 11:7. All patients were symptomatic at presentation and four (22.22%) had atypical symptoms (obstructive jaundice, bladder outlet obstruction, and acute abdominal pain). Liver HC was more common than lung HC. Three patients (16.6%) had synchronous involvement of the lung and liver/spleen. All the patients underwent surgical excision of the cyst as none of them responded to preoperative pharmacotherapy. Open surgery was done in 15 patients and laparoscopic excision was carried out in three (16.6%). Two patients had abnormal communications (cysto-biliary/cysto-bronchial), which were managed successfully. Neither any major perioperative morbidity nor mortality was nor any recurrence was seen in a 2-year clinical follow-up, no significant perioperative morbidity or mortality occurred, and no recurrence was noted. In conclusion, single organ HC is more common in children, with more prevalence of hepatic than pulmonary HC. Early surgical excision of the cyst should be considered (preferably laparoscopic whenever possible) instead of pharmacotherapy.


Subject(s)
Cysts , Echinococcosis, Hepatic , Echinococcosis , Humans , Male , Child , Female , Echinococcosis/diagnosis , Echinococcosis/therapy , Albendazole/therapeutic use , Cysts/drug therapy
11.
Biosensors (Basel) ; 12(5)2022 May 09.
Article in English | MEDLINE | ID: mdl-35624612

ABSTRACT

Echinococcosis is an important zoonotic infectious disease that seriously affects human health. Conventional diagnosis of echinococcosis relies on the application of large-scale imaging equipment, which is difficult to promote in remote areas. Meanwhile, surgery and chemotherapy for echinococcosis can cause serious trauma and side effects. Thus, the development of simple and effective treatment strategies is of great significance for the diagnosis and treatment of echinococcosis. Herein, we designed a phototheranostic system utilizing neutrophil-membrane-camouflaged indocyanine green liposomes (Lipo-ICG) for active targeting the near-infrared fluorescence diagnosis and photothermal therapy of echinococcosis. The biomimetic Lipo-ICG exhibits a remarkable photo-to-heat converting performance and desirable active-targeting features by the inflammatory chemotaxis of the neutrophil membrane. In-vitro and in-vivo studies reveal that biomimetic Lipo-ICG with high biocompatibility can achieve in-vivo near-infrared fluorescence imaging and phototherapy of echinococcosis in mouse models. Our research is the first to apply bionanomaterials to the phototherapy of echinococcosis, which provides a new standard for the convenient and noninvasive detection and treatment of zoonotic diseases.


Subject(s)
Echinococcosis , Nanoparticles , Animals , Biomimetics , Echinococcosis/diagnostic imaging , Echinococcosis/therapy , Indocyanine Green/therapeutic use , Liposomes , Mice
12.
J Paediatr Child Health ; 58(7): 1193-1200, 2022 07.
Article in English | MEDLINE | ID: mdl-35262239

ABSTRACT

AIM: Echinococcosis with multi-organ/disseminated involvement is rare in childhood. We aimed to evaluate the clinical and laboratory characteristics and prognosis in paediatric patients with echinococcosis having multiorgan/disseminated involvement. METHOD: We evaluated retrospectively children with echinococcosis with involvement of three or more organs. RESULTS: Thirteen patients were included in the study. The median age was 120 (range 71-189) months. Three (23%) were diagnosed incidentally. Abdominal pain was seen in 5 (38.4%) patients, vomiting in 4 (30.7%), headache in 3 (23%), cough in 2 (15.3%), groin pain in 1 (7.6%), 1 (7.6%) had jaundice and 1 (7.6%) had fever. The median duration of complaints was 48 (0-140) days. The most common tripartite organ was 38.4% (5/13) liver, lung and spleen. Isolated abdominal dissemination was detected in two patients. Two patients had multi-organ involvement and multiple cysts with dissemination. Cyst rupture was observed in three of the patients; recurrent urinary tract infection, hydroureteronephrosis, secondary peritonitis with intra-abdominal abscess, and biliary tract fistula were each observed in one patient. Relapse developed in 3 (23%) patients. CONCLUSION: Echinococcosis is a very slow growing and complex parasitic disease that affects many organs and tissues. In our study, eosinophilia, recurrence, and complications were seen at a higher rate in paediatric patients with multiorgan involvement, who required repetitive surgeries and long-term medical treatment. However, there are scanty data on risk factors, optimum treatment and prognosis.


Subject(s)
Echinococcosis/pathology , Abdomen , Abdominal Pain , Adolescent , Child , Echinococcosis/complications , Echinococcosis/diagnosis , Echinococcosis/therapy , Humans , Liver/parasitology , Liver/pathology , Lung/parasitology , Lung/pathology , Retrospective Studies , Spleen/parasitology , Spleen/pathology
13.
PLoS Negl Trop Dis ; 16(1): e0010175, 2022 01.
Article in English | MEDLINE | ID: mdl-35100287

ABSTRACT

BACKGROUND: Alveolar echinococcosis (AE) can cause severe liver fibrosis and could be fatal if left untreated. Currently, there are no effective therapeutic options for AE-induced liver fibrosis. In view of the therapeutic potential of adipose-derived stem cells (ADSCs), we investigated whether ADSCs transplantation has the ability to control or reverse fibrosis progression in the liver of Echinococcus multilocularis (E. multilocularis) infected mice. METHODOLOGY/PRINCIPAL FINDINGS: C57BL/6 mice infected with E. multilocularis through portal vein inoculation were intravenously injected with ADSCs isolated from inguinal adipose tissues of 6-8 weeks old mice. Histopathological analysis including heamatoxylin & eosin staining as well as Masson's trichrome staining, and Sirius red staining were performed to access the degree of liver fibrosis. Histopathological examination 30 days after ADSCs transplantation revealed that ADSCs significantly decreased the degree of liver fibrosis in E. multilocularis infected mice by inhibiting the expressions of α-SMA and type 1 collagen deposition. In addition, compared to the non-transplanted group, ADSCs transplantation reduced fibrotic areas in E. multilocularis infected mice. We also found that ADSCs transplantation significantly down-regulated TGF-ß1 and TGF-ßR expressions, while up-regulating Smad7 expression in the TGF-ß/Smad signaling pathway. CONCLUSIONS: ADSCs can alleviate Echinococcus multilocularis infection-induced liver fibrosis by modulating the activity level of the TGF-ß/Smad7 signaling pathway and provide a potential therapeutic approach for E. multilocularis-induced fibrosis.


Subject(s)
Echinococcosis/complications , Liver Cirrhosis/therapy , Mesenchymal Stem Cell Transplantation , Animals , Collagen/metabolism , Echinococcosis/therapy , Echinococcus multilocularis/pathogenicity , Mesenchymal Stem Cells/cytology , Mesenchymal Stem Cells/physiology , Mice, Inbred C57BL
14.
PLoS Negl Trop Dis ; 15(11): e0009927, 2021 11.
Article in English | MEDLINE | ID: mdl-34818327

ABSTRACT

The metacestode stage of Echinococcus granulosus can cause cystic echinococcosis (CE), which still widely occurs around the world. Since the early 1970s, benzimidazoles have been shown to inhibit the growth of cysts and used to treat CE. However, benzimidazoles are still ineffective in 20%-40% of cases. In order to explore the new agents against CE, we have investigated the therapeutic effect of the recombinant adenoviral vector expressing mouse IL-28B (rAd-mIL-28B) on protoscoleces-infected mice. In our study, we successfully established the model mice which infected with protoscoleces intraperitoneally. At 18 weeks post-infection, the mice received rAd-mIL-28B (1×107 PFU) weekly by intramuscular injection for 6 weeks. Compared with the untreated control (13.1 ± 2.2 g), there was a significant reduction in cysts wet weight in rAd-mIL-28B group (8.3 ± 3.5 g) (P < 0.05), especially in Albendazole (ABZ) + rAd-mIL-28B group (5.8 ± 1.4 g) (P < 0.01). We also observed the severe damage of the germinal layer and the laminated layer of cysts after treatment. rAd-mIL-28B group showed a prominent increase in the level of Th1 type cytokines (such as IFN-γ, IL-2 and TNF-α). Meanwhile, the frequency of Foxp3+ T cells was decreased in the rAd-mIL-28B group (4.83 ± 0.81%) and ABZ + rAd-mIL-28B group (4.60 ± 0.51%), comparing with the untreated group (8.13 ± 2.60%) (P < 0.05). In addition, compared with the untreated control (122.14 ± 81.09 pg/ml), the level of IFN-γ significantly increased in peritoneal fluid in the rAd-mIL-28B group (628.87 ± 467.16 pg/ml) (P < 0.05) and ABZ + rAd-mIL-28B group (999.76 ± 587.60 pg/ml) (P < 0.001). Taken together, it suggested that ABZ + IL-28B may be a potential therapeutic agent against CE.


Subject(s)
Albendazole/administration & dosage , Anthelmintics/administration & dosage , Cytokines/genetics , Echinococcosis/therapy , Echinococcus granulosus/drug effects , Echinococcus granulosus/growth & development , Adenoviridae/genetics , Adenoviridae/metabolism , Animals , Combined Modality Therapy , Cytokines/immunology , Echinococcosis/drug therapy , Echinococcosis/immunology , Echinococcosis/parasitology , Echinococcus granulosus/physiology , Female , Humans , Mice , Mice, Inbred BALB C , Th1 Cells/immunology , Th17 Cells/immunology
16.
Rev Med Suisse ; 17(748): 1466-1473, 2021 Sep 01.
Article in French | MEDLINE | ID: mdl-34468098

ABSTRACT

Hepatic cystic echinococcosis (HCE), is a cosmopolitan parasitic zoonosis. Autochtonous HCE cases are rare and the majority of cases are imported from endemic areas. It induces the development in the liver of Echinococcus granulosus larvae. Extrahepatic localizations are also possible. Cyst development is slow with an often-late diagnosis. In Switzerland, HCE discovery is usually fortuitous, during an abdominal radiological examination. More rarely, an acute clinical picture reveals a complication that can be severe or even fatal. The diagnosis is based on ultrasound findings that allows cyst characterization according to the WHO classification. This guides the therapeutic choice: simple monitoring, albendazole therapy, percutaneous procedures or surgery.


L'échinococcose kystique hépatique (EKH) est une zoonose parasitaire cosmopolite. Les cas d'EKH autochtones sont rares et la majorité est importée par des patients originaires de zones d'endémie. L'EKH est due au développement dans le foie de la larve d'Echinococcus granulosus. Des localisations extrahépatiques sont également possibles. Son évolution est lente avec un diagnostic fréquemment tardif. En Suisse, celui-ci est souvent fortuit, à l'occasion d'un examen radiologique abdominal. Plus rarement, un tableau clinique aigu et bruyant révèle une complication qui peut être sévère, voire mortelle. Le diagnostic basé sur l'échographie permet la caractérisation du kyste selon la classification de l'OMS. Celle-ci guide le choix thérapeutique: surveillance simple, traitement par albendazole, gestes percutanés ou chirurgie.


Subject(s)
Echinococcosis , Echinococcus granulosus , Albendazole/therapeutic use , Animals , Echinococcosis/diagnostic imaging , Echinococcosis/therapy , Humans , Liver , Zoonoses
17.
Pan Afr Med J ; 39: 15, 2021.
Article in English | MEDLINE | ID: mdl-34394806

ABSTRACT

Primary musculoskeletal echinococcosis is rare and accounts for 2-3% of the patients with hydatid disease. We report a case of giant primary hydatid cysts of the thigh and the gluteal region in an 82-year-old female, who presented with a painful multiple palpable mass. The diagnosis was confirmed by imaging and serology. Total resection was performed through an extended lateral approach of the thigh and intraoperative findings revealed infected giant hydatid cysts. The postoperative outcome was uneventful. Albendazole drug (400mg per day) was given for the next 3 months. At 6 months follow-up, the patient was satisfied with no complications or recurrence.


Subject(s)
Albendazole/administration & dosage , Anthelmintics/administration & dosage , Echinococcosis/diagnosis , Aged, 80 and over , Buttocks/parasitology , Combined Modality Therapy , Echinococcosis/therapy , Female , Follow-Up Studies , Humans , Thigh/parasitology
18.
Front Immunol ; 12: 691364, 2021.
Article in English | MEDLINE | ID: mdl-34248983

ABSTRACT

Background: To explore the relationship between the preoperative immune inflammation index (SII) and the prognostic nutritional index (PNI) and the overall survival rate (OS) of patients with alveolar hydatid disease. Methods: The clinical data of patients with hepatic alveolar echinococcosis treated by surgery in the Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of Qinghai University from January 2015 to January 2019 were analyzed retrospectively, and the SII, PNI, PLR and NLR were calculated. Spearman correlation analysis was utilized to analyze the correlation among SII, PNI, PLR and NLR. Receiver operating characteristic curve (ROC) was utilized to determine the best intercept values of SII, PNI, PLR and NLR, and Chi-square test was used to evaluate the relationship between SII, PNI and various clinicopathological features in patients with hepatic alveolar echinococcosis. The kaplan-Meier method was used to draw survival curves and analyze the relationship between them and the total survival time of patients. A cox regression model was used to analyze the relationship between SII, PNI and the prognosis of patients with hepatic alveolar echinococcosis. Finally, ROC curve was used to estimate the predictive efficacy of SII, PNI and COSII-PNI for the prognosis of patients with hepatic alveolar echinococcosis. Results: A total of 242 patients were included, including 96 males and 146 females, aged 11.0-67.0 (36.6 ± 11.7) years. The values of SII, PNI, PLR and NLR are calculated, and the best truncation values of SII, PNI, PLR and NLR are given in ROC curve. The kaplan-Meier survival curve was used to analyze the relationship between SII, PNI, PLR, NLR and the overall survival time of patients with hepatic alveolar echinococcosis. The results showed that the median follow-up time was 45 months (95%CI: 39.484-50.516), and the average survival time was 49 months (95%CI: 47.300-51.931), which was low p<0.001); The 5-year OS rate of low PNI was significantly lower than that of high PNI group (37.7% vs 71.6%; p<0.001); The 5-year OS rate in low PLR group was significantly higher than that in high PLR group (70.4% vs 24.3%; p<0.001); The 5-year OS rate in low NLR group was significantly higher than that in high NLR group (67.2% vs 28.8%; p<0.001). Cox unifoliate analysis showed that SII, PNI, PLR and NLR were important prognostic factors related to OS. Cox multivariate analysis showed that SII(HR=4.678, 95% CI: 2.581-8.480, P<0.001) and PNI(HR=0.530, 95%CI: 0.305-0.920, P<0.05) were identified as independent risk indicators of OS, while NL was identified as independent risk indicators of OS ROC curve analysis showed that AUC of SII, PNI, PLR, NLR and COSII-PNI were 0.670(95%CI: 0.601-0.738), 0.638(95%CI: 0.561-0.716) and 0.618(95% CI: 0.541-0.694), respectively COSII-PNI is superior to SII and PNI in evaluating prognosis (P < 0.05). Conclusions: SII and PNI can be regarded as independent risk factors reflecting the prognosis of patients with hepatic alveolar echinococcosis. The lower SII and the higher PNI before operation, the better the prognosis of patients, and the combined application of SII and PNI before operation can improve the accuracy of prediction.


Subject(s)
Echinococcosis , Liver Diseases , Adolescent , Adult , Aged , Child , Echinococcosis/immunology , Echinococcosis/mortality , Echinococcosis/surgery , Echinococcosis/therapy , Female , Humans , Inflammation/immunology , Inflammation/mortality , Inflammation/surgery , Inflammation/therapy , Kaplan-Meier Estimate , Leukocyte Count , Liver/surgery , Liver Diseases/immunology , Liver Diseases/mortality , Liver Diseases/surgery , Liver Diseases/therapy , Male , Middle Aged , Nutrition Assessment , Palliative Care , Platelet Count , Preoperative Period , Prognosis , Young Adult
19.
Yale J Biol Med ; 94(2): 271-275, 2021 06.
Article in English | MEDLINE | ID: mdl-34211347

ABSTRACT

Aim: Zoonotic parasite infections affect many pregnant people around the world. Hydatid cystic disease is also a zoonotic disease caused by Echinococcus sp. This study aims to present the maternal-fetal results and clinical treatment of pregnant women diagnosed with liver hydatid cyst (CH). This zoonotic disease is discussed again in the light of current literature. Materials and Methods: Pregnant women with hydatid cyst monitored in a tertiary health center between 2018 and 2020 were evaluated. Seven cases were included in this study. We retrospectively collected and analyzed clinical data, which did not interfere with medical treatment. Results: Albendazole was started as medical therapy in six patients, and percutaneous drainage was applied to one patient. Three of our six patients who started medical treatment had to undergo surgery due to maternal complications that developed despite medical treatment. Two of our patients were delivered with a cesarean section due to the obstetric indications. Discussion: Hydatid cysts are most commonly caused by Echinococcus granulosus infection and most common in the liver. The diagnosis of liver hydatid cysts is not difficult, but pregnant women's treatment methods have some problems. Although both medical and surgical treatments are available, there is no consensus. We would also like to underscore that echinococcal disease of the liver should be kept in mind in the differential diagnosis of abdominal pain, jaundice, and/or fever, especially in endemic regions. We think that when we increase awareness about this disease, we can improve fetal and maternal outcomes by making an early diagnosis and management.


Subject(s)
Echinococcosis , Echinococcus , Animals , Cesarean Section , Echinococcosis/diagnosis , Echinococcosis/therapy , Female , Humans , Pregnancy , Retrospective Studies , Zoonoses
SELECTION OF CITATIONS
SEARCH DETAIL
...